A 25 year-old male who has been taking finasteride (1mg/day) for 4 months and then switching to dutasteride (0.5mg twice per week) for 20 months, with positive results; the difference between finasteride and dutasteride is discussed.
Higher doses of dutasteride reduce scalp DHT more effectively than finasteride, but have diminishing returns after 3mg daily and may cause more side effects. Combining dutasteride with topical minoxidil can enhance results, but using both finasteride and dutasteride together is unnecessary.
The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.
A user shared their 3-year experience using finasteride for hair loss, reporting significant improvement and no side effects. They are now starting dutasteride and plan to update on progress in a year.
OP used 1mg finasteride for 4 years, then had a hair transplant, and for the past 6 months has been using 0.5mg dutasteride and 2.5mg oral minoxidil twice daily. The treatments resulted in significant hair density and thickness improvement.
A user ordered Alpha Plus from Anagenica, expecting it to contain specific percentages of Fin, Estradiol, Minoxidil, and CB0301. However, the received product's label showed different percentages, including a surprising 25% CB, leading the user to question its safety and accuracy.
A user switched from finasteride to dutasteride and experienced continuous shedding but is now seeing some regrowth. Others shared similar experiences, noting that shedding can continue but hair often improves over time with dutasteride.
GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.
A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.
The conversation is about someone experiencing hair regrowth using Minoxidil and Dutasteride, along with other treatments. They report their hairline is improving and their forehead appears smaller.
The user has been using dutasteride, RU58841, and minoxidil for hair loss, experiencing some side effects and mixed results, with RU58841 notably reducing scalp itch. Despite extensive treatment, the user has maintained hair but struggles with hairline thickening.
The user experienced improved self-confidence and hair regrowth using finasteride, minoxidil, and dermarolling. Visible results were noted after about three months, with microneedling done once a week.
Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.
Fluridil's effectiveness and safety in treating hair loss are discussed, with higher concentrations showing potential success. Comparisons are made to other treatments like RU58841, Pyri, CB-03-01, and topical spironalactone.
The conversation is about seeking updates on the hair loss treatment RCH-01, specifically its next phase and any news from Shiseido. The user recalls someone being in contact with a researcher or company representative.
A 42-year-old man achieved significant hair regrowth in seven months using oral minoxidil, oral dutasteride, topical minoxidil, microneedling, and supplements. He experienced minimal side effects and noted dramatic improvements in hair thickness and health.
A product called HairMDL includes Minoxidil, Dutasteride, Latanoprost, caffeine, Tretinoin, and Triamcinolone. Users are curious about its effectiveness and safety, particularly regarding the topical steroid Triamcinolone.
The user is using 0.1% dutasteride, 1% minoxidil with 2% procapil and 0.005% caffeine in the morning, and 1% minoxidil with 2% procapil and 0.01% tretinoin at night. They are concerned about the solution vehicle's effectiveness in preventing systemic absorption and ensuring the products stay around the hair follicles.
After switching from finasteride to 0.5 mg dutasteride daily, the user experienced thinner hair but no shedding. They are considering continuing dutasteride and possibly using oral minoxidil, while also dealing with allergy-like symptoms possibly unrelated to the medication.
A woman experiencing hormonal hair loss is on dutasteride and bicalutamide, which initially improved her hair, but she is now experiencing a second shedding phase with significant short hair loss. Despite normal hormone levels and no deficiencies, she is unsure if this shedding is normal and seeks advice.
The conversation is about someone's experience with hair loss and their progress using dutasteride, a treatment for hair loss. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
A 42-year-old is using dutasteride, oral and topical minoxidil, ketoconazole, and a dermaroller for hair loss, with noticeable progress after six months. They are questioning if further gains are possible and considering stopping the dermaroller, as advised that future improvements may only involve hair thickening.
The conversation is about whether the Ordinary's Multi-Peptide Serum for hair density can be mixed with finasteride. A video was mentioned that shows the serum being mixed with Stemoxydine.
The user switched from finasteride to 2.5 mg dutasteride daily and added 1% pyrilutamide to address persistent scalp itch, but the itch remains. They also use 2% ketoconazole and 2.5% selenium sulfide shampoo for temporary relief.
User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.
The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.
The conversation discusses impressive results from a 28-day application of a hair loss treatment. Users compare it to their experiences with Minoxidil and Dutasteride, noting excitement over the new findings.
The user experienced significant hair regrowth using dutasteride (0.5 mg three times a week) and RU58841 (5% once a day), with no side effects reported from RU58841. They are considering increasing the RU58841 dose or adding minoxidil for further improvement.